MCB-613 exploits a collateral sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer through covalent inhibition of KEAP1 https://www.biorxiv.org/content/10.1101/2023.01.17.524094v1?med=mas
MCB-613 exploits a collateral sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer through covalent inhibition of KEAP1 https://www.biorxiv.org/content/10.1101/2023.01.17.524094v1?med=mas